30 closest matches · ranked by relevance
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Neuroendocrine Tumors · Carcinoma, Small Cell Lung · Neuroendocrine Carcinoma
Primary: Phase 1: Maximum Tolerated Dose of PEN-221 and Recommended Phase 2a Dose (RP2D) — 18.0 mg
Small Cell Lung Cancer · Small Cell Lung Cancer Extensive Stage
Primary: Phase I - Recommended Phase II Dose (RP2D) of 177Lu-DOTA0-Tyr3-Octreotate — 7.4 GBq
Neuroendocrine Tumors · Neuroendocrine Neoplasm · Gastroenteropancreatic Neuroendocrine Tumor
Primary: Overall Survival Rate at 12 Months — 54.1 % of participants
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Neuroendocrine Carcinoma of the Lung and Thymus
Primary: Percentage of Participants Progression-free at 9 Months Based on Response Evaluation Criteria In Solid Tumors v1.1 (RECIST v1.1) — 0; 0; 0; 2.4 percentage of participants
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Large-Cell Neuroendocrine Carcinoma
Primary: Sequencing Rate (Feasibility)
Limited Stage Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 14.5; 10.7 months
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Gastroenteropancreatic Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) — 0.045 proportion of participants
Small Cell Lung Cancer
Primary: Overall Survival — 8.1; 10.6 months — p=<0.01
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Small Cell Lung Cancer
Primary: One-year Survival, The Percentage of Patients Who Are Alive One Year After Completing Protocol Treatment — 54 percentage of participants
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Prostate Cancer
Primary: Number of Participants With Overall Response as Determined by iRECIST — 1; 1; 3; 9 Participants
Neuroendocrine Carcinoma
Primary: Net Change Relative to Baseline in Tumor Blood Flow — -0.44; -0.12; -0.60; -0.40 ml/min/100gm
Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 1 Participants
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Neuroendocrine Tumors
Primary: 12-month Progression Free Survival (PFS) — 64.7 percentage of participants w/ 12 mo PFS
Extensive Stage Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 5.88; 5.85 Months — p=0.8072
Well-differentiated Non-functional NET of Thoracic Origin · Well-differentiated Non-functional NET of Gastrointestinal Origin · Well-differentiated Non-functional NET of Pancreatic Origin
Primary: Overall Response Rate (ORR) by RECIST 1.1 and as Per Blinded Independent Central Review (BIRC). — 7.4; 4.8 Percentage of participants
Neuroendocrine Tumor · Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate — 0.0 percentage of patients
Carcinoma, Small Cell
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 57 percentage of participants
Neuroendocrine Tumors
Primary: Best Response Rate by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 Upon Central Radiologic Assessment — 0; 0; 23; 9 Participants